Brief: Perspective Therapeutics Announces First Patient Dosed With Vmt01 Monotherapy In A Phase 1/2A Study Of MC1R-Positive Metastatic Melanoma
11/04/2025 12:04
April 11 (Reuters) - Perspective Therapeutics Inc CATX.A: PERSPECTIVE THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED WITH 212PBVMT01 MONOTHERAPY AT 1.5 MCI IN A PHASE 1/2A STUDY OF MC1R-POSITIVE METASTATIC MELANOMA Source text: ID:nGNXRTx8P Further company coverage: CATX.A (((( Reuters.briefs@thomsonreuters.com ;));))
Recent news on Perspective Therapeutics
See all newsPerspective Therapeutics Q2 net loss widens on higher R&D costs
Brief: Perspective Therapeutics Q2 EPS USD -0.22
Brief: Perspective Therapeutics Expands Therapeutic Focus Areas First Patient Dosed With Vmt-Α-Net In The Meningioma Cohort Of A Phase 1/2A Study
Brief: Perspective Therapeutics Q1 EPS USD -0.25
Perspective Therapeutics rises as experimental cancer drug shows promise